Within the limitation of limited numbers in both animal experiments and clinical applications, our data suggest that Kit M (containing the clinically approved drugs GM-CSF and PGE1) is able to produce DC/DCleu in vivo in both leukemia-diseased rats and humans. Here, CSF2 is linked to leukemia.